Literature DB >> 7310641

Pharmacokinetics of propranolol.

L Borgström, C G Johansson, H Larsson, R Lenander.   

Abstract

The pharmacokinetics of propranolol after the administration of 40, 80, and 120 mg p.o. and 10 mg i.v. was studied in nine healthy male volunteers. Propranolol was analyzed after extraction and derivatization by gas-liquid chromatography. A multiexponential curve-stripping program was used for the pharmacokinetic analysis. The volume of distribution was about 6 liters . kg-1, bioavailability around 25%, with a mean terminal half-life of 6 hr. There was no evidence of either dose dependent disposition kinetics or an oral threshold dose. A slight increase in urine volume was observed after propranolol administration.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7310641     DOI: 10.1007/bf01060886

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  18 in total

1.  Spuriously low plasma propranolol concentrations resulting from blood collection methods.

Authors:  R H Cotham; D Shand
Journal:  Clin Pharmacol Ther       Date:  1975-11       Impact factor: 6.875

2.  [Effect of propranolol on urine concentration].

Authors:  J L Imbs; M O Spach; M Scmidt; J Schwartz
Journal:  Therapie       Date:  1977 May-Jun       Impact factor: 2.070

3.  Pharmacokinetics of propranolol in normal healthy volunteers.

Authors:  R Gomeni; G Bianchetti; R Sega; P L Morselli
Journal:  J Pharmacokinet Biopharm       Date:  1977-06

4.  Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man.

Authors:  G H Evans; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

5.  A sensitive gas chromatographic method for the determination of propranolol in human plasma.

Authors:  E Di Salle; K M Baker; S R Bareggi; W D Watkins; C A Chidsey; A Frigerio; P L Morselli
Journal:  J Chromatogr       Date:  1973-09-26

6.  Pharmacokinetics of dextro-, laevo- and racemic propranolol in man.

Authors:  C F George; T Fenyvesi; M E Conolly; C T Dollery
Journal:  Eur J Clin Pharmacol       Date:  1972-03       Impact factor: 2.953

7.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

8.  Studies on the absorption, distribution and excretion of propranolol in rat, dog and monkey.

Authors:  A Hayes; R G Cooper
Journal:  J Pharmacol Exp Ther       Date:  1971-02       Impact factor: 4.030

9.  Comparison of the pharmacokinetics of intravenous dl-propranolol in borderline and permanent hypertension.

Authors:  Y A Weiss; M E Safar; C Chevillard; A Frydman; A Simon; P Lemaire; J M Alexandre
Journal:  Eur J Clin Pharmacol       Date:  1976       Impact factor: 2.953

10.  Beta-blockade and blood-levels after low-dose oral propranolol: The hepatic "first-pass" threshold revisited.

Authors:  R Davies; T G Pickering; A Morganti; G Bianchetti; P L Morselli; J Romankiewicz; J H Laragh
Journal:  Lancet       Date:  1978-02-25       Impact factor: 79.321

View more
  9 in total

Review 1.  Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.

Authors:  Peer Tfelt-Hansen; Frederik Nybye Ågesen; Agniezka Pavbro; Jacob Tfelt-Hansen
Journal:  CNS Drugs       Date:  2017-05       Impact factor: 5.749

2.  Multi-functional scaling methodology for translational pharmacokinetic and pharmacodynamic applications using integrated microphysiological systems (MPS).

Authors:  Christian Maass; Cynthia L Stokes; Linda G Griffith; Murat Cirit
Journal:  Integr Biol (Camb)       Date:  2017-04-18       Impact factor: 2.192

3.  Determinants of Propranolol's Selective Effect on Loss Aversion.

Authors:  Peter Sokol-Hessner; Sandra F Lackovic; Russell H Tobe; Colin F Camerer; Bennett L Leventhal; Elizabeth A Phelps
Journal:  Psychol Sci       Date:  2015-06-10

Review 4.  Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics.

Authors:  D Wiest
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

5.  Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions.

Authors:  A J Byrne; J J McNeil; P M Harrison; W Louis; A M Tonkin; A J McLean
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

6.  Propranolol pharmacokinetics in infants treated for Infantile Hemangiomas requiring systemic therapy: Modeling and dosing regimen recommendations.

Authors:  Laurence Del Frari; Christine Léauté-Labrèze; Laurent Guibaud; Sébastien Barbarot; Jean-Philippe Lacour; Christine Chaumont; Alain Delarue; Jean-Jacques Voisard; Valérie Brunner
Journal:  Pharmacol Res Perspect       Date:  2018-04-30

7.  PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol.

Authors:  David G Levitt
Journal:  BMC Clin Pharmacol       Date:  2002-08-15

8.  Propranolol reduces reference-dependence in intertemporal choice.

Authors:  Karolina M Lempert; Sandra F Lackovic; Russell H Tobe; Paul W Glimcher; Elizabeth A Phelps
Journal:  Soc Cogn Affect Neurosci       Date:  2017-09-01       Impact factor: 3.436

9.  Population Pharmacokinetics and Pharmacodynamics of Oral Propranolol in Pediatric Patients With Infantile Hemangioma.

Authors:  Tomoki Takechi; Tadao Kumokawa; Rumiko Kato; Takeshi Higuchi; Tsuyoshi Kaneko; Ichiro Ieiri
Journal:  J Clin Pharmacol       Date:  2018-05-10       Impact factor: 3.126

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.